Sign Up to like & get
recommendations!
1
Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.05.006
Abstract: In our recent paper [(1)][1], we demonstrated that both B-type natriuretic peptide (BNP) and N-terminal pro-BNP at baseline and during treatment with angiotensin receptor-neprilysin inhibitor (ARNI) were found to be independently and comparably associated with…
read more here.
Keywords:
arni;
searching optimal;
reply searching;
prognostic marker ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz746.0392
Abstract: Angiotensin receptor-neprilysin inhibitor (ARNI) increases natriuretic peptide and improves heart failure. We previously reported that ARNI has the effects of suppression of myocardial hypertrophy and fibrosis in addition to reduction of afterload by natriuretic effect.…
read more here.
Keywords:
arni;
neprilysin inhibitor;
group;
ctl group ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2024 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000001639
Abstract: Supplemental Digital Content is Available in the Text. Abstract: Sodium–glucose cotransporter 2 inhibitors (SGLT2Is) and angiotensin receptor–neprilysin inhibitor (ARNI) may cause potential renal damage, the combined impact of SGLT2Is and ARNI on acute kidney injury…
read more here.
Keywords:
arni;
sglt2is arni;
arni acute;
kidney injury ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2018 at "Heart"
DOI: 10.1136/heartjnl-2018-ics.47
Abstract: Background Heart failure is one of the leading causes of morbidity and mortality in cardiovascular patients. This places significant burden on the health service in Ireland- accounting for 7% of all HSE inpatient bed days.…
read more here.
Keywords:
arni;
heart;
class;
treatment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2025 at "Biomedicines"
DOI: 10.3390/biomedicines13092265
Abstract: Background/Objectives: Angiotensin receptor–neprilysin inhibitor (ARNI) has a well-established advantage over angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) therapy in patients (pts) with heart failure with reduced ejection fraction (HFrEF), but in pts after acute…
read more here.
Keywords:
post infarction;
arni;
lvef;
acei arb ... See more keywords